It hasn't taken bioMerieux-Pierre Fabre SAlong to act. Founders Alain Merieux and Pierre Fabre insisted when they agreed to merge their companies last fall that one of the key attractions would be to bolster bioMerieux's position in diagnostics and Pierre Fabre's in pharmaceuticals (see bioMerieux's and Pierre Fabre's Surprise, IN VIVO, October 2000 [A#2000800180 [See Deal]); in rapidly consolidating industries, both French companies were simply too small to be effective. Now, two months after the deal closed, the new company is proposing to pay $322 million for the clinical diagnostics businesses of Organon Teknika NV, the health care unit of Dutch conglomerate Akzo Nobel NV —roughly 1 1/4 times Organon's clinical diagnostics sales of $250 million.
The deal would combine two players with strong interests in microbiology and infectious disease testing—albeit with different strengths in each....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?